Show an ad over header. AMP

I am the second

Malaria vaccine from Oxford's COVID-19 team highly effective in early trials

A malaria vaccine developed by Oxford University was found to have "high-level efficacy" in phase II trials, according to a pre-print study released on Friday.

Why it matters: Malaria kills over 400,000 people a year, more than half of them children under the age of 5. Deaths have fallen in half over the past 20 years thanks to investment in prevention and drugs, but a truly effective malaria vaccine would represent one of the greatest victories in the history of public health.

Keep reading... Show less

Related Articles

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories